Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 128 for “"rifampicin"”.
-
Assay for Rifampicin Resistant M13 RF Synthesis
… strands in the presence of the antibiotic rifampicin. A segment of DNA carrying the sequence recognized by the replication protein n' has been isolated from bacteriophage ØX174 and cloned into an Ml3 bacteriophage vector. Protein n' is a component of the bacterial primosome, a multi-protein …
-
Characterization of the Hepatotoxicity of Rifampicin and Isoniazid
<p>In a mouse model, rifampicin and isoniazid combination treatment results in cholestatic liver injury that is associated with an increase of protoporphyrin ix (PPIX), the penultimate heme precursor. Excess PPIX is believed to bind to bile acids, precipitate in bile canaliculi, and form bile plugs …
-
Characterization and Pharmacokinetics of Rifampicin Laden Carboxymethylcellulose Acetate Butyrate Particles
… and potentially lethal infectious human disease. Rifampicin is a front line anti-tuberculosis drug usually prescribed in combination with isoniazid, pyrazinamide and streptomycin for a period of six to seven months. When given orally for the treatment of MTB, rifampicin exhibits low …
-
Investigating the Double-Edged Sword of Rifampicin Resistance in Mycobacterium Tuberculosis
… that is resistant to the first line antibiotic rifampicin (Rif). Rif resistant (RifR) Mtb caused up to 450,000 cases of TB and 264,000 deaths worldwide in 2021. Treatment for drug resistant TB is even more arduous, consisting of expensive second- and third-line antituberculars with side effects …
-
Characterization of Mycobacterium tuberculosis isolates with discordant rifampicin susceptibility test results
… National TB Control programme in December 2010. Rifampicin (RIF) resistance detected by the Xpert MTB/RIF (Xpert) is confirmed by a line probe assay (LPA) (GenoType MTBDRplus) and/or phenotypic (culture-based) drug susceptibility testing (DST) by MGIT (Mycobacterial Growth Indicator Tube) on the …
-
Rifampicin-resistant Mycobacterium tuberculosis: an emerging threat to human health in Botswana
Rifampicin-resistant tuberculosis (RR-TB) continues to threaten global TB control. The World Health Organisation (WHO) estimated that 400,000 people developed RR-TB in 2023, with Africa being among the regions with the highest burden. Botswana, a high TB/HIV burden country, has reported an increase …
-
Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
The global burden of rifampicin- and/or multidrug-resistant (RR/MDR) -TB, i.e. Mycobacterium tuberculosis resistant to rifampicin and/or isoniazid is increasing, especially in settings with high HIV prevalence. Optimising the prevention and treatment of RR/MDR-TB in children in such settings is …
-
Untersuchung der Kombinationsbehandlung Rifampicin/Ceftriaxon im Vergleich zur Ceftriaxon-Monotherapie bei der experimentellen bakteriellen Meningitis
… die Entzündungsparameter nach der Behandlung mit Rifampicin, gefolgt von Ceftriaxon, im Tiermodell deutlich niedrigere Werte aufwiesen, als nach Ceftriaxon-Monotherapie.
-
The Epidemiology and Evolution of Rifampicin Mono Resistant Tuberculosis in Khayelitsha, Cape Town, South Africa
… World Health Organization Global TB report 2018, rifampicin monoresistant tuberculosis (RMR-TB) comprises 22% and 38% of all rifampicin-resistant TB (RR-TB) globally, and within South Africa, respectively. National surveys from South Africa show an increasing proportion of RMR-TB among TB cases …
-
The pharmacokinetics of lopinavir in HIV-infected adults receiving rifampicin with adjusted doses of lopinavir
… the drug-drug interactions between the PIs and rifampicin, with an emphasis on LPV/r.
-
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis
… characterising the extent to which concomitant rifampicin-based TB treatment decreases nevirapine plasma concentration therefore remain important.
-
Determinants and consequences of the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in a cohort of tuberculosis patients
… patients with tuberculosis (TB) susceptible to rifampicin and isoniazid at Brewelsleloof Hospital, Worcester, in the Western Cape.
-
Strategies for optimising TB-HIV co-treatment in children and adolescents with drug-susceptible tuberculosis on rifampicin-based standard regimens
… in children and adolescents receiving rifampicin-based TB therapy, nested within two clinical trials across four African countries. First, we assessed the World Health Organization's (WHO) weight-band dosing recommendations for first-line TB drugs using fixed-dose combination tablets. …
-
Rifampicin-resistant tuberculosis in Botswana: barriers and risk factors influencing patient outcomes, case detection, and linkage to effective care and treatment
… Botswana reports high treatment success for rifampicin-resistant tuberculosis (RR-TB), but many challenges remain. Case detection is lower than expected and varies by year, and mortality rates are high. Research aims included identifying: factors associated with mortality, access to culture …
-
Population pharmacokinetic models describing drug-drug interactions and variability in HIV infected South Africans on protease inhibitor-based antiretroviral regimens with and without tuberculosis
… current World Health Organization guidelines. Rifampicin, a key component of antituberculosis treatment, profoundly reduces lopinavir concentrations. Therefore, investigation of the optimal dosage regimens of lopinavir/ritonavir when co-administered with rifampicin-based antituberculosis …
-
Nonlinear mixed-effects modelling of drug-drug interactions between antiretroviral therapy and tuberculosis treatment
… interactions (DDIs), mediated especially by rifampicin, a key component of the TB regimen and potent enzyme and transporter inducer. These DDIs may compromise treatment safety and efficacy, potentially leading to therapeutic failure and increased risk of drug resistance. In this thesis, we …
-
Development of an in vitro drug recovery model for paediatric tuberculous meningitis using microdialysis with in vivo application
… data of unbound drugs in ventricular CSF using rifampicin in TBM as a model in vitro and in vivo. Aims: We aimed to establish a novel technique, using MD to continually measure Rifampicin in ventricular CSF of TBM patients. This involved 1) developing an appropriate system that could be used …
-
Genomics study of anti-tuberculosis drug-induced hypersensitivity reactions
… susceptibility in patients with confirmed rifampicin and or isoniazid-associated hypersensitivity reactions using both genome- wide association studies and candidate gene approaches. Methods: A case control study using 14 patients with previous tuberculosis-associated CADR who were …
Page 1 of 7